Advertisement

Topics

AstraZeneca and Chi-Med begin Phase III trial of savolitinib for PRCC

19:00 EDT 29 Jun 2017 | Net Resources International

AstraZeneca and Hutchison China MediTech (Chi-Med) have started a Phase III SAVOIR clinical trial of savolitinib to treat patients with papillary renal cell carcinoma (PRCC).

Original Article: AstraZeneca and Chi-Med begin Phase III trial of savolitinib for PRCC

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca and Chi-Med begin Phase III trial of savolitinib for PRCC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...